Kura Oncology Enters Material Definitive Agreement
Ticker: KURA · Form: 8-K · Filed: Jul 1, 2025 · CIK: 1422143
| Field | Detail |
|---|---|
| Company | Kura Oncology, INC. (KURA) |
| Form Type | 8-K |
| Filed Date | Jul 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement
TL;DR
Kura Oncology just signed a big deal, details TBD.
AI Summary
On June 27, 2025, Kura Oncology, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its counterparty, or any associated financial terms.
Why It Matters
This filing indicates a significant new development for Kura Oncology, potentially involving partnerships, acquisitions, or licensing deals that could impact its future operations and stock value.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement, necessitating further information to assess the risk.
Key Players & Entities
- Kura Oncology, Inc. (company) — Registrant
- June 27, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- ZETA ACQUISITION CORP III (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by Kura Oncology?
The filing states that Kura Oncology, Inc. entered into a material definitive agreement on June 27, 2025, but does not specify the details of the agreement.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the name of the other party involved in the material definitive agreement.
Are there any financial terms or obligations associated with this agreement?
The provided text of the 8-K filing does not include any information regarding financial terms or obligations related to the material definitive agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 27, 2025.
What is Kura Oncology's principal executive office address?
Kura Oncology, Inc.'s principal executive offices are located at 12730 High Bluff Drive, Suite 400, San Diego, CA 92130.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 1, 2025 regarding Kura Oncology, Inc. (KURA).